William Blair & Company
GALT icon

William Blair & Company’s Galectin Therapeutics GALT Stock Holding History

William Blair & Company’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$417K Buy
149,283
+111,399
+294% +$339K ﹤0.01% 1211
2025
Q4 		$158K Hold
37,884
– – ﹤0.01% 1507
2025
Q3 		$160K Hold
37,884
– – ﹤0.01% 1499
2025
Q2 		$79.9K Hold
37,884
– – ﹤0.01% 1551
2025
Q1 		$46.2K Hold
37,884
– – ﹤0.01% 1600
2024
Q4 		$48.9K Hold
37,884
– – ﹤0.01% 1611
2024
Q3 		$104K Hold
37,884
– – ﹤0.01% 1533
2024
Q2 		$85.6K Hold
37,884
– – ﹤0.01% 1532
2024
Q1 		$90.5K Hold
37,884
– – ﹤0.01% 1521
2023
Q4 		$62.9K Hold
37,884
– – ﹤0.01% 1565
2023
Q3 		$72.7K Hold
37,884
– – ﹤0.01% 1546
2023
Q2 		$54.6K Hold
37,884
– – ﹤0.01% 1588
2023
Q1 		$79.6K Hold
37,884
– – ﹤0.01% 1526
2022
Q4 		$42.8K Sell
37,884
-3,000
-7% -$4K ﹤0.01% 1594
2022
Q3 		$67K Hold
40,884
– – ﹤0.01% 1555
2022
Q2 		$54K Buy
+40,884
New +$58.8K ﹤0.01% 1620
2021
Q4 		– Sell
-10,756
Closed -$42K – 1992
2021
Q3 		$42K Hold
10,756
– – ﹤0.01% 1698
2021
Q2 		$34K Hold
10,756
– – ﹤0.01% 1730
2021
Q1 		$23K Hold
10,756
– – ﹤0.01% 1737
2020
Q4 		$24K Hold
10,756
– – ﹤0.01% 1689
2020
Q3 		$29K Hold
10,756
– – ﹤0.01% 1551
2020
Q2 		$33K Hold
10,756
– – ﹤0.01% 1486
2020
Q1 		$21K Sell
10,756
-23,364
-68% -$56.8K ﹤0.01% 1482
2019
Q4 		$98K Hold
34,120
– – ﹤0.01% 1413
2019
Q3 		$125K Buy
34,120
+23,364
+217% +$84.4K ﹤0.01% 1352
2019
Q2 		$45K Buy
+10,756
New +$46.6K ﹤0.01% 1509

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

William Blair & Company's GALT Position: Q1 2026 in Review

William Blair & Company increased its Galectin Therapeutics (GALT) stake by 294% in Q1 2026, buying an estimated $339K and bringing the position to 149,283 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #1211.

William Blair & Company first reported a position in GALT in Q2 2019 and has held it in 26 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • William Blair & Company held 149,283 shares of Galectin Therapeutics worth $417K as of Q1 2026.
  • William Blair & Company bought 111,399 Galectin Therapeutics shares in Q1 2026, an estimated $339K.
  • Galectin Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1211 holding.
  • William Blair & Company first reported a position in Galectin Therapeutics in Q2 2019 and has held it in 26 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.